search
Back to results

Plasma Citrulline Concentration in Tropical Enteropathy

Primary Purpose

Malabsorption Syndromes, Granulomatous Enteritis, Enteritis

Status
Completed
Phase
Locations
Zambia
Study Type
Observational
Intervention
Sponsored by
Azienda Ospedaliero-Universitaria di Parma
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Malabsorption Syndromes focused on measuring citrulline, malabsorption, Villous atrophy, enteropathy

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • histologically ascertained Tropical enteropathy
  • Mixed HIV status
  • Body mass index within normal range

Exclusion Criteria:

  • Patients with surgical resection of stomach, duodenum or pancreas; or (UGI) bypass.
  • Patients with other important disease, which may interfere with the study (especially diabetes and renal impairment). Alcoholism, drug abuse or any other circumstances, which may compromise the patient's ability to comply with the study requirements.
  • Pregnancy
  • Patients experiencing diarrhoea within one month since enrolment date
  • Use of glucagon-like peptide 2 (GLP2), growth hormone (GH) or glutamine or triglycerides
  • Coeliac Disease, Crohn's disease or infectious intestinal disease
  • Patients on steroids or FANS
  • Oral feeding>1.0-fold the estimated basal metabolic rate as assessed using Harris and Benedict equation

Sites / Locations

  • Department of Medicine, University of Zambia School of Medicine, University Teaching Hospital

Outcomes

Primary Outcome Measures

postabsorptive plasma citrulline concentration

Secondary Outcome Measures

intestinal permeability ratio

Full Information

First Posted
January 2, 2009
Last Updated
January 2, 2009
Sponsor
Azienda Ospedaliero-Universitaria di Parma
search

1. Study Identification

Unique Protocol Identification Number
NCT00816842
Brief Title
Plasma Citrulline Concentration in Tropical Enteropathy
Official Title
Plasma Citrulline as Quantitative Biomarker of HIV Associate Villous Atrophy in a Tropical Enteropathy Population
Study Type
Observational

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
October 1998 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
September 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Azienda Ospedaliero-Universitaria di Parma

4. Oversight

5. Study Description

Brief Summary
Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood stream. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with tropical enteropathy of mixed HIV status. The focus will be on the ability of the intestine to sustain the individual concerned from a nutritional standpoint. The investigators hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.
Detailed Description
Preliminary studies reported that plasma citrulline concentrations may be a reliable biochemical marker for intestinal dysfunction and absorptive enterocyte mass. The relationship between citrulline concentration and intestinal function has been supported in other studies including those examining rejection in small bowel allografts. Concentrations of citrulline are dramatically reduced in cases of mucosal damage (e.g. moderate graft rejection or viral enteritis)and strongly correlate (inversely) with severity on biopsy. Plasma citrulline concentration is lower also in patients with villous atrophy (24±13µmol/L)than in healthy subjects (40±10µmol/L)and patients with anorexia nervosa (39±9µmol/L).Experimental studies have been carried out also in assessing the value of citrulline as a marker for severity of small bowel epithelial damage from radiation and viral infections. The plasma citrulline was shown to be a simple, non invasive and sensitive essay to monitor and quantify radiation and/or chemotherapy induced small bowel damage in mice and humans. Otherwise, the literature on citrulline as a potential marker of intestinal and nutritional integrity is young and consistent data for specific conditions as for HIV enteropathy are missing.We hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malabsorption Syndromes, Granulomatous Enteritis, Enteritis, HIV Enteropathy, Ileal Diseases
Keywords
citrulline, malabsorption, Villous atrophy, enteropathy

7. Study Design

Primary Outcome Measure Information:
Title
postabsorptive plasma citrulline concentration
Time Frame
within two years since enrolment date
Secondary Outcome Measure Information:
Title
intestinal permeability ratio
Time Frame
within two years since enrolment date

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: histologically ascertained Tropical enteropathy Mixed HIV status Body mass index within normal range Exclusion Criteria: Patients with surgical resection of stomach, duodenum or pancreas; or (UGI) bypass. Patients with other important disease, which may interfere with the study (especially diabetes and renal impairment). Alcoholism, drug abuse or any other circumstances, which may compromise the patient's ability to comply with the study requirements. Pregnancy Patients experiencing diarrhoea within one month since enrolment date Use of glucagon-like peptide 2 (GLP2), growth hormone (GH) or glutamine or triglycerides Coeliac Disease, Crohn's disease or infectious intestinal disease Patients on steroids or FANS Oral feeding>1.0-fold the estimated basal metabolic rate as assessed using Harris and Benedict equation
Study Population Description
Tropical enteropathy with mixed HIV status
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cinzia Papadia, MD
Organizational Affiliation
Azienda Ospedaliero-Universitaria di Parma
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alastair Forbes, BSc MD FRCP ILTM
Organizational Affiliation
University College London Hospitals
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Antonio Di Sabatino, MD
Organizational Affiliation
University of Pavia
Official's Role
Study Director
Facility Information:
Facility Name
Department of Medicine, University of Zambia School of Medicine, University Teaching Hospital
City
Lusaka
State/Province
Lusaka province
ZIP/Postal Code
P/B RW1X
Country
Zambia

12. IPD Sharing Statement

Learn more about this trial

Plasma Citrulline Concentration in Tropical Enteropathy

We'll reach out to this number within 24 hrs